CTNNB1 and breast carcinoma: In fact, there have been proposals for targeting CTNNB1 as the main player in the WNT canonical pathway in breast cancer as with 3,6-dihydroxyflavone in MDA-MB-231 cell line (Anastas and Moon 2013), even though many unknowns remain (van Schie and van Amerongen 2020).